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ABSTRACT
We investigated thevalueofgenetic, histopathologic, andearly treatment response information inprognosing long-
term renal outcome in children with primary steroid-resistant nephrotic syndrome. From the PodoNet Registry, we
obtained longitudinal clinical information for 1354 patients (disease onset at.3months and,20 years of age): 612
haddocumentedresponsiveness to intensifiedimmunosuppression (IIS),1155hadkidneybiopsyresults,and212had
an established genetic diagnosis. We assessed risk factors for ESRD using multivariate Cox regression models.
Complete and partial remission of proteinuria within 12 months of disease onset occurred in 24.5% and 16.5% of
children, respectively, with the highest remission rates achievedwith calcineurin inhibitor–basedprotocols. Ten-year
ESRD-free survival rates were 43%, 94%, and 72% in children with IIS resistance, complete remission, and partial
remission, respectively; 27% in children with a genetic diagnosis; and 79% and 52% in children with histopathologic
findings of minimal change glomerulopathy and FSGS, respectively. Five-year ESRD-free survival rate was 21% for
diffuse mesangial sclerosis. IIS responsiveness, presence of a genetic diagnosis, and FSGS or diffuse mesangial
sclerosis on initial biopsy as well as age, serum albumin concentration, and CKD stage at onset affected ESRD risk.
Our findings suggest that responsiveness to initial IIS and detection of a hereditary podocytopathy are prognostic
indicators of favorable and poor long-term outcome, respectively, in children with steroid-resistant nephrotic syn-
drome.Childrenwithmultidrug-resistant sporadicdisease showbetter renal survival than thosewithgeneticdisease.
Furthermore, histopathologic findings may retain prognostic relevance when a genetic diagnosis is established.
J Am Soc Nephrol 28: 3055–3065, 2017. doi: https://doi.org/10.1681/ASN.2016101121
Although most children with idiopathic nephrotic
syndrome readily respond to glucocorticoid therapy,
approximately 10% of patients turn out to be steroid
resistant (steroid-resistant nephrotic syndrome
[SRNS]). The predominant histopathologic finding
associated with steroid resistance is FSGS. SRNS/
FSGSisassociatedwithan increasedriskofdeveloping
ESRD. Patients with SRNS/FSGS account for 15% of
Received October 23, 2016. Accepted April 17, 2017.
Published online ahead of print. Publication date available at
www.jasn.org.
Correspondence: Dr. Franz Schaefer, Division of Pediatric Ne-
phrology, Center for Pediatrics and Adolescent Medicine, Im
Neuenheimer Feld 430, 69120 Heidelberg, Germany. Email:
franz.schaefer@med.uni-heidelberg.de
Copyright © 2017 by the American Society of Nephrology
J Am Soc Nephrol 28: 3055–3065, 2017 ISSN : 1046-6673/2810-3055 3055
all childrenwith CKD requiring RRT.1 However, disease courses
are highly variable, indicating etiologic heterogeneity of the dis-
order. Although a considerable proportion of patients respond
to intensified immunosuppression (IIS) protocols, others show
multidrug resistance. IIS-responsive forms of SRNS may show
better long-term outcomes than IIS-resistant forms.2 In addi-
tion, in recent years, abnormalities in a growing number of genes
specifically expressed in podocytes have been identified as un-
derlying causes of SRNS. Comprehensive genetic screening cur-
rently identifies hereditary podocytopathies in up to 30% of
children with SRNS.3
Historically, the prognosis of SRNSwas largely staged accord-
ing to histopathologic findings, with limited predictability of
medium- to long-term disease outcomes.4–9 The recent insights
should allow reclassification of SRNS taking into account infor-
mation about genetic disease causes and IIS responsiveness.
However, most SRNS cohorts assessing long-term outcomes
on the basis of genetic information and IIS responsiveness
were limited in size, follow-up time, and/or completeness of
information. Important open questions concern the prognostic
effect of partial versus complete proteinuria remission in re-
sponse to IIS, the relative roles of IIS responsiveness, genetic
disease, histopathologic findings and other potential risk mod-
ifying factors, such as age and disease severity at onset, and the
frequency and relevance of the anecdotally reported responsive-
ness of genetic SRNS forms to IIS.
In thework presented here, we sought to address these open
issues by interrogating the PodoNet Registry database. In this
international patient registry comprehensive clinical, bio-
chemical, treatment-related, genetic, and histopathologic in-
formation is collected from pediatric patients with primary
steroid resistance with up to 15 years of follow-up.10 The av-
erage duration of follow-up from first disease manifestation
was 3.6 years in this cohort.
RESULTS
Patient Characteristics
In total, 1354 patients with 10,409 clinical updates were in-
cluded in the analysis (Figure 1). These included 713 patients
with sporadic disease and negative genetic testing, 212
patients in whom a genetic cause was ascertained (Supple-
mental Table 1), 139 patients with familial disease without
established genetic diagnosis, and 290 patients with sporadic
disease occurrence in whom no testing was performed. In-
formation on the type of and response to immunosuppres-
sive therapies during the first year after disease onset was
available in 612 children (Figure 1). Detailed patient char-
acteristics of the overall cohort and each subgroup are given
in Table 1.
Efficacy of IIS Protocols
In total, 906 individual treatment periods were recorded in
612 patients during the first year from disease onset; 380 pa-
tients were treated with one immunosuppressive medication,
173 patients were treated with two different immunosuppres-
sive medications, and 59 patients were treated with three or
more different immunosuppressive medications. The treat-
ment results are provided in Tables 1 and 2. Altogether, com-
plete remission of proteinuria was observed with 18.5% of
therapies and in 24.5% of patients. The highest rates of com-
plete or partial remission were achieved with calcineurin
inhibitor (CNI)–based protocols, whereas steroid pulses, cy-
clophosphamide (CPH), and mycophenolate mofetil (MMF)
showed lacking efficacy in .80% of patients.
Among the 502 patients with sporadic disease without a
genetic diagnosis, 139 (27.3%) achieved complete remission,
and another 87 (17.3%) achieved partial remission. Similar
response rates were observed among 36 patients with familial
disease but without established genetic diagnosis, with 11
(31%) patients achieving complete remission and six (17%)
patients achieving partial remission. In the subgroup of pa-
tients with familial genetically unexplained disease, none of
17 children with IIS responsiveness but four of 19 IIS-
unresponsive children progressed to ESRD. One of three kidney
transplant recipients developed post-transplant proteinuria
recurrence.
Among 74 children with a documented genetic diagnosis,
transient complete remission was documented in two (2.7%)
children, andpartial remissionwasdocumented in eight (11%)
children. The detailed genetic information is given in Supple-
mental Table 2. One patient with a WT1 mutation achieved
complete remission on cyclosporin A (CsA) and methylpred-
nisolone pulses for 2 weeks followed by mild subnephrotic-
range proteinuria. The partial remission status was maintained
for.11 years. At last follow-up, 12 years after disease onset, the
patient was still in CKD stage 2. The other patient, compound
heterozygous in NPHS2, also showed transient complete remis-
sion for 4–6 weeks before a relapse was documented. He pro-
gressed to ESRD within 4 years. Partial remission with reduction
of proteinuria to the non-nephrotic range was observed in eight
patients with genetic disease while receiving CsA and four pa-
tients receiving CsA combined with RAAS antagonists. Five of
these eight patients were nephrotic, and four were in CKD stages
3–5 at last observation.
Long-Term Renal Survival
According to Kaplan–Meier analysis, the proportion of pa-
tients with SRNS and preserved renal function was 74%
(95% confidence interval [95% CI], 71% to 77%) at 5 years,
58% (95% CI, 53% to 61%) at 10 years, and 48% (95% CI,
43% to 53%) at 15 years.
Ten-year renal survival was 94% (95% CI, 87% to 97%)
among patients who achieved complete remission in the first
disease year, 72% (95%CI, 47% to 86%) in thosewho achieved
partial remission, and 43% (95% CI, 35% to 51%) in the
patients with multidrug resistance (log rank: P,0.001).
Fifteen-year survival was 94% (95% CI, 87% to 97%) in com-
plete responders to initial IIS compared with 37% (95% CI,
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28% to 46%) in the multidrug-resistant cohort (log rank:
P,0.001) (Figure 2 and Supplemental Figure 1).
Analysis of the data including hereditary and genetic in-
formation showed excellent long-term outcomes in IIS-sensitive
patients with SRNS and sporadic disease occurrence (96%;
95% CI, 90% to 99%, 10- and 15-year renal survival rates).
The diagnosis of a genetic disease markedly affected ESRD risk:
10- and 15-year ESRD-free survival rates were 27% (95% CI,
20% to 35%) and 17% (95%CI, 10% to 25%) in patients with a
genetic diagnosis compared with 53% (95% CI, 44% to 61%)
and 48% (95% CI, 37% to 58%) in patients with sporadic
multidrug-resistant disease without a genetic diagnosis (log
rank: P,0.001) (Figure 3 and Supplemental Figure 2).
Further breakdown by genetic diagnosis showed largely uni-
form renal survival times of the major genetic entities, with esti-
mated 10-year ESRD-free survival rates of 28% (95% CI, 16% to
42%) for NPHS2-associated nephropathy, 23% (95% CI, 10% to
39%) forWT1-associateddisease, and29%(95%CI, 19%to42%)
for the less common podocytopathies (Supplemental Figure 3).
Notably, patients with familial disease but without estab-
lished genetic diagnosis showed better 10-year renal survival
(67%; 95%CI, 55% to 77%) than patientswith a genetic diagno-
sis (log rank: P,0.001) (Figure 3 and Supplemental Figure 2).
The 501 patients with sporadic disease occurrence in the
cohort in whom no IIS response information (n=279) at all and
no response information during the first 12 months (n=222) were
documented suffered a 10-year ESRD risk of 32% (95% CI, 26%
to 38%), likely representing amixture of patients with andwithout
IIS responsiveness.
The histopathologic findings at the time
of diagnosis were strongly associated with
long-term renal survival (Supplemental
Figure 4). ESRD-free survival rates in chil-
dren with minimal change glomerulopathy
(MCGN) MCGN were 92% (95% CI, 86%
to 95%) at 5 years and 79% (95% CI, 69%
to 86%) at 10 and 15 years compared with
69% (95% CI, 65% to 73%) 5-year, 52%
(95% CI, 46% to 57%) 10-year, and 37%
(95%CI, 30% to 44%) 15-year renal survival
rates in children diagnosed with FSGS. The
most unfavorable outcome was observed in
patients with diffuse mesangial sclerosis
(DMS) who have an 80% (95% CI, 60% to
93%) ESRD risk at 5 years after initial
manifestation.
Cox regression analysis was performed
to identify predictors of renal survival in
unadjusted, hereditary disease–adjusted,
and multivariate models (Table 3). An age
of 1–5 years at disease onset was associated
with a lower ESRD risk, whereas advanced
CKD at initial presentation and nephrotic-
range proteinuria increased the likelihood
of progressing to ESRD both in the univar-
iate models and when adjusting for hereditary disease. Age
1–5 years old and advanced CKD at first presentation but not
nephrotic-range proteinuria remained significant risk factors
for ESRD in the fully adjusted multivariate model. The histo-
pathologic diagnosis was clearly predictive of ESRD. Even ad-
justed for age, proteinuria level, CKD, genetic status, and IIS
responsiveness, DMS (hazard ratio, 12.3; 95% CI, 6.3 to 24.0)
or FSGS (hazard ratio, 2.9; 95% CI, 1.9 to 4.5) on biopsy
implied an increased risk of progressing to ESRD. Moreover,
the independent effect of genetic diagnosis and IIS responsive-
ness suggested in the Kaplan–Meier survival analysis was con-
firmed by multivariate Cox regression modeling. The ESRD
risk was increased by 150% in patients in whom a genetic di-
agnosis was shown and reduced by 87% in patients who
achieved complete remission and by 50% in those with partial
remission in response to IIS during the first year. These asso-
ciations were still present after adjustment for the characteris-
tics at disease onset and histologic diagnosis.
DISCUSSION
This integrative analysis of the largest global cohort of pediatric
SRNS provides unequivocal evidence for the independent
prognostic effect of an established genetic diagnosis, the his-
topathologic findings at disease onset, and the early respon-
siveness of proteinuria to IIS therapy.
The averageoverall ESRD-free survival rates in this unselected
cohort of pediatric patients with primary SRNS were 74% at 5
Figure 1. Distribution of the selected PodoNet Registry cohort. Selection of patients
for IIS response and renal survival analyses from the total PodoNet Registry cohort.
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years and 48% at 15 years after diagnosis, well in line with pre-
vious cohort studies reporting 65%–92%renal survival at 5 years
and 34%–76% at 15 years.5,6,9,11,12 We used the extensive infor-
mation collected in the PodoNet Registry to delineate key factors
helping to predict long-term renal outcome.
A strong predictive value of the responsiveness to initial CNI
therapy in SRNS for long-term renal survival has recently been
reported in a multicenter study of 169 children with primary
SRNS.2 Our analysis confirms and extends this observation to
IIS therapies in general, with 10- and 15-year kidney survival
rates differing by asmuch as 50% between patients who achieved
complete proteinuria remission in the year after diagnosis and
those who were found to be multidrug resistant. The predictive
value of IIS responsiveness remained highly significant when the
genetic diagnosis was taken into account and was also indepen-
dent of the histopathologic diagnosis as well as age, renal func-
tion, and clinical presentation at disease onset. Calcineurin
inhibitionwas found to be themost efficacious immunosuppres-
sive therapy, yielding complete remission in 30% of all patients
and partial remission in another 19% of all patients. This finding
is in keeping with previous reports, in which CNI response rates
ranged from 31% to 89% for complete remission and from 19%
to 38% for partial remission depending on the selection criteria
chosen.13–17 By contrast, we observed full remission in,10% of
patients exposed to steroid pulses, CPH, orMMF, in keepingwith
previous studies.18–23Ourfindings provide some evidence against
the use of these therapeutic protocols. In accordance with our
results, amuch lower proteinuria response rate and poorer long-
term renal survival with CPH were observed in a recent pro-
spective study comparing this agent with CsA in children with
SRNS.18 Our findings lend further support to the current con-
sensus thatCPH should not beused in SRNSdue to its poor risk-
benefit profile.18–25 Likewise, we provide further evidence that
MMF is of very limited efficacy in inducing proteinuria remis-
sion in pediatric SRNS as suggested by two small-scale pediatric
studies.26,27
In a sizable fraction of patients exposed to IIS, protein ex-
cretion was not completely normalized but was reduced to the
subnephrotic range. It is often difficult to causally attribute this
partial remissionpattern to the administered immunosuppres-
sive therapies due to the frequent coadministration of RAAS
antagonists, which reliably lower proteinuria by 40%–50% in
patients with SRNS.28,29 Notwithstanding this potential
source of confounding, it is noteworthy that partial reduction
of proteinuria in the first year after diagnosis in patients
receiving IIS was associated with significantly improved
long-term renal survival relative to that in patients with mul-
tidrug-resistant proteinuria. Even when adjusting for genetic
and histopathologic findings, age, initial disease severity, and
renal function, partial responsiveness to initial IIS was associ-
ated with a reduction of the ESRD risk by .50%.
In 20.2% of the included patients (age at disease onset .3
months old but ,20 years old), a genetic podocytopathy was
identified. Although NPHS2 and WT1 mutations accounted for
two thirds of patients, the other abnormalities were scattered over
17 different podocyte genes (Supplemental Table 1). Children in
whom a genetic diagnosis was established carried a highly unfa-
vorable long-term prognosis, with 85% progressing to ESRD
within 15 years. Notably, this outcome was significantly poorer
than that of children with sporadic multidrug-resistant disease in
whom no genetic abnormality was established, highlighting the
added prognostic value obtained from genetic screening.
The observed difference in outcome between the genetic and
themultidrug-resistantcaseswithoutageneticdiagnosismayeven
beunderestimated, because a fractionofmultidrug-resistant chil-
dren was not screened comprehensively in the more recently
identified genes or did not undergo genetic screening at all.
Among the 43% of patients in our cohort who underwent next
generation gene panel sequencing (NGS), a genetic diagnosis was
established in 23%. A recent large study using NGS panel screen-
ing identified genetic causes in 29% of an SRNS cohort including
patients with congenital disease.3
Table 2. Response to IIS treatment episodes during the first year after disease onset in 612 patients with SRNS
Treatment Episodes (6Oral Steroid, 6RAS) Complete Remission Partial Remission No Remission Total
Oral
CNI 129 (29.8) 82 (18.9) 222 (51.3) 433
CPH 9 (9.2) 8 (8.2) 81 (82.7) 98
MMF 2 (8.3) 2 (8.3) 20 (83.3) 24
CNI + MMF 4 (11.8) 10 (29.4) 20 (58.8) 34
iv Pulse
Steroid pulse 16 (6.8) 25 (10.6) 195 (82.6) 236
iv + Oral
Steroid pulse + CNI 4 (8.2) 5 (10.2) 40 (81.6) 49
Steroid pulse + other 1 (5.9) 1 (5.9) 15 (88.2) 17
CPH pulse 6 other 1 (12.5) 1 (12.5) 6 (75.0) 8
Rituximab 6 other 2 (28.6) 0 5 (71.4) 7
All first-year treatment episodes 168 (18.5) 134 (14.8) 604 (66.7) 906
Best response in treated patients 150 (24.5) 101 (16.5) 361 (59.0) 612
In total, 232 (38%) patients were treated with more than one treatment protocol during the first year after disease onset. Most efficacious treatment was used to
classify patients. Data are given as number (percentage). RAS, renin-angiotensin system; CPH, cyclophosphamide.
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Our study contributes important information to the ongo-
ing controversy of whether some patients diagnosed with
genetic disease may still respond to immunosuppressive treat-
ment. Specifically, a nonimmunologic antiproteinuric action
of CNI mediated by stabilization of the actin cytoskeleton has
been suggested.30 Our 74 patients with a genetic disease and
documented IIS represent the largest published cohort of pa-
tients with hereditary SRNS treated with IIS. Only two of
these, one diagnosed with WT1 and one diagnosed with
NPHS2 glomerulopathy, transiently achieved complete remis-
sion in the first year of disease while on CsA treatment. The
patient with WT1 disease (previously published31) still has
stable renal function after 12 years of follow-up; the other
patient progressed to ESRD within ,5 years. Another eight
patients achieved the criteria for partial remission for some
time while receiving CsA. However, remission persisted in
none of the children followed for .30 months, and four of
five childrenwith long-term follow-upwere in CKD stages 3–5
at last observation. Also, 50% of the children were cotreated
with RAAS antagonists, which may explain the observed re-
duction of proteinuria. Our data confirm observations of
previous case series and small studies gen-
erally suggesting nonresponsiveness to IIS
in hereditary podocytopathies.32–36 Com-
plete proteinuria remission on calcineurin
inhibition has been reported in only four
subjects, and partial remission on calci-
neurin inhibition has been reported in 17
subjects to date, almost all of whom were
simultaneously receiving RAAS antago-
nists.2,31,32,37,38 Nearly all reported patients
had a poor long-term renal outcome.
Hence, the current state of evidence allows
concluding that, in hereditary forms of
SRNS, calcineurin inhibition does not
offer a therapeutic benefit over RAAS
blockade alone, and hence, patients should
be spared the side effects of immunosup-
pressive therapy.
Another interesting subgroup is made up
of the 139 patients with familial SRNS in
whom no known genetic disease could be
identified by NGS gene panel screening.
Some 31% of the children with documented
first-year IIS achieved complete remission, a
rate similar to that observed in childrenwith
sporadic disease without a genetic diagnosis.
None of the IIS responders with familial
disease progressed to ESRD. One of three
transplant recipientswith familial disease de-
veloped post-transplant recurrence. The
long-term renal survival rate of the patients
with genetically unexplained familial cases
(67% at 10 years) was 15% better than that
of the patients with sporadic cases with
multidrug resistance and almost 40% better than that of the
patients with an established genetic diagnosis. It is interesting
to speculate about as-yet undiscovered genetic entities in these
families, which might involve variants in genes regulating the
immune systemrather thanpodocyte structure and functionand
may, in some patients, show sensitivity to pharmacologic mod-
ulation.The favorable response to IIS ingeneral and theobserved
case of post-transplant recurrence are suspicious for an immu-
nologic pathogenesis in these patients with familial cases and
provide a rationale for a trial of IIS therapy in patients with
familial cases in whom no genetic diagnosis can be established.
Traditionally, the diagnostic categorization and prognostic
judgment in SRNS relied on the histopathologic assessment of
kidney tissue. In this cohort, we expectedly found that the
diagnosis of FSGS associated with a fourfold increase of
ESRD risk relative to MCGN and that the diagnosis of DMS
associated with a 20-fold increase of ESRD risk relative to
MCGN. Notably, FSGS and DMS largely retained their inde-
pendent prognostic value when adjusting for CKD stage at first
manifestation, responsiveness to IIS, and the presence of a
genetic disease. Hence, a patients who is multidrug resistant
Figure 2. Renal survival, analysed by response to IIS, is excellent in children with SRNS
achieving full remission following IIS compared to patients being resistant to IIS. Ten-year
ESRD-free survival rates were 94% (95%CI, 87% to 97%) in patients achieving full remission,
72% (95%CI, 48% to 86%) in patients with partial remission, and 43% (95%CI, 35% to 51%)
in patients resistant to IIS.
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with a genetic diagnosis and a given GFRwill still have a nearly
threefold higher ESRD risk when diagnosed with FSGS com-
paredwithMCGN, suggesting that histopathologic assessment
may be still relevant in the genetic era. Because the prognostic
value of renal biopsy is still unproven in genetic SRNS, further
detailed studies will be required to address which histopatho-
logic features are most predictive in patients with IIS-resistant
SRNS with or without an established genetic disease.
Although the very large size of the cohort and the compre-
hensive and long-term data collection are major strengths of
this international study, it is, at the same time, limited by the
incompleteness of reporting. We attempted to maximize ge-
netic information byNGS gene panel sequencing of all patients
who did not achieve complete remission by IIS but were able to
retrieveDNA samples in only 85%of these individuals. Finally,
the common use of polypragmatic therapeutic approaches
with frequent coadministration of RAAS blockers was a major
source of confounding to the analysis of treatment responses.
Nonetheless, thePodoNet cohort proved to be aunique source
of information on short- and long-term outcomes in children
with primary SRNS.We found clear evidence
that the response to initial immunosuppres-
sive therapy and the diagnosis of an underly-
inggeneticdiseaseare important independent
prognostic indicators in addition to the his-
topathologic diagnosis, age, and renal func-
tion at first presentation.
CONCISE METHODS
Patient Cohort and Analytic
Approach
The PodoNet Registry is an international web-based
clinical registry (www.podonet.org) for primary
SRNS and congenital nephrotic syndrome (CNS).
The PodoNet Registry accepts patients with
childhood-onset (age #20 years old) primary
SRNS,CNS, or persistent subnephrotic proteinuria
with likely genetic disease. Patients with secondary
SRNS are not included in this cohort. The registry
study protocol, description, and characterization of
the PodoNet cohort were recently published.10
For these analyses, patients with CNS , pa-
tients with adult disease onset, and patients
without clinical outcome information were ex-
cluded. Hence, of 1840 patients registered in the
PodoNetRegistry, 1354unrelated children ages 3
months old to 20 years old at disease onset with
available longitudinal clinical information were
selected (Figure 1). In case of several registered
family members, one representative family
member was randomly selected and included
into the analyses. The included patients were
treated at 62 centers in 21 countries. In 612 pa-
tients, sufficient informationwas available to evaluate the response to
different immunosuppressive treatment strategies within 12 months
after disease onset (Figure 1, Table 1).
Theprevalenceofgeneticdiseasewas20.2%in theanalysis cohort, from
which CNS was excluded. Disease-causing gene variants were primarily
identified by Sanger sequencing of individual genes in 107 of 607 patients
and NGS of 30 podocytopathy-associated genes in 105 of 457 patients.
IIS therapies used forfirst-, second-, and third-line treatment after
confirming steroid resistance (persistent nephrotic-range proteinuria
after 4-week treatment with oral prednisone at 60 mg/m2 per day)
included intravenous steroid pulses, CNIs, MMF, CNI combined
with MMF, oral or intravenous CPH, and rituximab.
The diagnosis of steroid resistance and the response to IIS were
evaluated according to a standardized set of criteria taking into ac-
count changes in proteinuria and serum albumin.
As previously defined,10 complete remission after IIS was diag-
nosed in case of proteinuria reduction to,100 mg/m2 24-hour pro-
tein excretion,,0.2 mg/mg protein-to-creatinine ratio in spot urine
(if age ,2 years old: ,0.5 mg/mg), a negative dipstick reading, or
serum albumin .30 g/L combined with dipstick trace (+).
Figure 3. The analysis of renal survival by disease category showed an excellent
long-term outcome in IIS sensitive SRNS patients with sporadic disease occurrence
and poor long-term outcome in patients with genetic disease. IIS resistant patients
with sporadic disease had a better renal survival compared to patients with genetic
disease (patients with partial IIS responsiveness were classified IIS resistant for this
analysis).
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Partial remission was defined as persistent non-nephrotic–range
proteinuria with a 24-hour protein excretion .100 mg/m2 per day
but,1 g/m2perday, urine protein-to-creatinine ratio of 0.2–2mg/mg (if
age,2 years old: 0.5–2mg/mg), dipstick 1+ in combinationwith serum
albumin .30 g/L, or dipstick trace (+) in combination with serum al-
bumin,30 g/L.
Lack of remission was defined as persistent nephrotic-range pro-
teinuria as defined by 24-hour protein excretion $1 g/m2 per day,
urine protein-to-creatinine ratio of .2 mg/mg, dipstick 2+ or
greater, or dipstick 1+ with serum albumin #30 g/L.
Because the propensity of achieving a favorable response to IIS
treatment may depend on the duration of IIS treatment and disease,
the evaluation of IIS responsiveness was limited to the first year after
disease onset tominimize potential bias. The evaluation timewindow
to assess responsiveness to an IIS protocol included the exposure time
plus the first 6 weeks after drug discontinuation if no medications
other thanoral steroids and/orRAASantagonistswere appliedduring
that period.
In patients who received more than one immunosuppressive
treatment in the first year, the most efficacious treatment and the
best antiproteinuric response were considered to classify IIS respon-
siveness. ESRDwas defined by attainment of CKD stage 5 and/or start
of RRT.
Statistical Analyses
Throughout the manuscript, data are given as medians (interquartile
ranges) or percentages relative to all patients with available information
regarding the item of interest. Kaplan–Meier analysis and log-rank tests
were used to analyze time to ESRD according to IIS responsiveness,
hereditary disease, and histopathologic diagnosis. Confidence limits
for proportions without ESRD are on the basis of normal approxima-
tion of log-log–transformed survival estimates.
Cox regression analyses were performed to identify risk factors
for ESRD. The analyses were stratified by treatment center to ac-
count for potential center effects. Small units contributing ,20
patients were considered as one center. Analyses were performed
in an unadjusted model, a model adjusting only for hereditary dis-
ease, and a multivariate model accounting for genetic diagnosis,
histopathologic diagnosis, degree of proteinuria, serum albumin,
age, CKD at disease onset, and IIS responsiveness. Additional co-
variates tested (but without significance in any of the models) were
sex and ethnicity.
Missing values for the variables CKD, proteinuria, and serum
albuminat disease onsetwere imputedon thebasis ofmissing at random
assumption using fully conditional specification methods.39,40 Ten
imputations were performed, and analysis results were pooled using
rules by Rubin.41
Table 3. Risk factors for ESRD according to unadjusted Cox regression analysis, a model adjusting for hereditary disease, and
a multivariate model
Variable
Unadjusted Adjusted for Hereditary Disease Multivariate Model
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Characteristics at disease onset
Age (reference $12 yr)
.3 mo and ,1 yr 1.21 0.81 to 1.85 0.34 0.99 0.62 to 1.44 0.79 0.88 0.55 to 1.39 0.60
$1 and ,6 yr 0.59 0.43 to 0.80 0.001 0.57 0.41 to 0.78 0.001 0.68 0.48 to 0.97 0.04
$6 and ,12 yr 0.91 0.65 to 1.28 0.59 0.93 0.66 to 1.30 0.66 1.16 0.80 to 1.68 0.44
Proteinuria (reference
subnephrotic range)
Nephrotic range 1.67 0.94 to 2.96 0.08 1.73 1.00 to 3.00 0.05 1.33 0.74 to 2.41 0.34
Serum albumin per 10-g/L increase 1.01 0.88 to 1.16 0.90 0.93 0.81 to 1.08 0.36 0.86 0.72 to 1.02 0.09
CKD (reference stage 1)
Stage 2 1.34 1.00 to 1.79 0.05 1.25 0.93 to 1.68 0.14 1.17 0.88 to 1.57 0.28
Stage 3 2.29 1.58 to 3.31 ,0.001 2.19 1.48 to 3.25 0.001 2.03 1.37 to 3.00 0.001
Stage 4 6.21 3.92 to 9.82 ,0.001 5.77 3.70 to 8.98 ,0.001 5.10 3.12 to 8.34 ,0.001
Histopathology (reference MCGN)
FSGS 3.96 2.57 to 6.08 ,0.001 3.61 2.34 to 5.56 ,0.001 2.90 1.85 to 4.53 ,0.001
DMS 19.9 10.7 to 37.0 ,0.001 13.2 7.01 to 25.0 ,0.001 12.3 6.29 to 24.0 ,0.001
MesPGN 1.69 0.93 to 3.07 0.09 1.49 0.82 to 2.72 0.19 1.26 0.68 to 2.35 0.46
Other 3.59 1.87 to 6.87 0.001 3.76 1.96 to 7.23 ,0.001 3.42 1.75 to 6.67 0.003
Unknown 4.81 2.91 to 7.95 ,0.001 3.88 2.34 to 6.44 ,0.001 3.59 2.13 to 6.04 ,0.001
Cause of disease (reference sporadic)
Familial 1.18 0.79 to 1.75 0.42 1.10 0.73 to 1.66 0.66
Genetic 3.11 2.45 to 3.94 ,0.001 2.39 1.83 to 3.13 ,0.001
Response to IIS (reference no remission)
Partial remission 0.34 0.18 to 0.63 0.001 0.42 0.23 to 0.79 ,0.01 0.49 0.26 to 0.92 0.03
Complete remission 0.11 0.05 to 0.24 ,0.001 0.14 0.06 to 0.31 ,0.001 0.13 0.06 to 0.30 ,0.001
Unknown 0.82 0.63 to 1.07 0.14 0.82 0.63 to 1.08 0.16 0.76 0.57 to 1.01 0.06
Only covariates with significant contribution to the model are shown. HR, hazard ratio; MCGN,minimal-change glomerulopathy; DMS, diffuse mesangial sclerosis;
MesPGN, mesangio-proliferative glomerulonephritis.
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Fully conditional specification (FCS) discriminant function, FCS
logistic regression, and FCS regression method were used for impu-
tation of CKD, proteinuria, and serum albumin, respectively. Impu-
tationwason thebasis of informationonage,CKD,proteinuria, serum
albumin, and closest available information as well as time to next
available information. Information on cause of disease was also used
for imputation of CKD and proteinuria.
P values were not adjusted for multiple comparisons due to the
exploratory character of the study. SAS, version 9.4 was used for all
statistical analyses.
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